Abstract: Compositions and methods for suppressing cancer cell growth by a synthetic chromatin effector. For example, a synthetic histone-binding regulator protein, polycomb-based transcription factor (PcTF), is utilized to activate suppression of cancer cell growth. Accordingly, an exemplary method disclosed herein may directly target a generally conserved feature, such as elevated trimethyl-lysine 27 on histone H3 (H3K27me3), with PcTF. In addition, a set of 19 PcTF-upregulated genes, or PUGs, that were consistent across three distinct breast cancer cell lines, were identified. These genes are associated with the interferon response pathway. The results demonstrate for the first time a chromatin-mediated interferon-related transcriptional response driven by an engineered fusion protein that physically links repressive histone marks with active transcription.

Abstract: The present invention relates to immunogenic immune complexes, related compositions, and related methods.

Abstract: The present disclosure provides a method of treating a neurodegenerative disorder, the method comprising administering a DNA methyltransferase inhibitor.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazolinedione structure which function as reactive oxygen species (ROS) inducers and inhibitors of mitochondrial activity within cancer cells (e.g., pancreatic cancer cells), and their use as therapeutics for the treatment of cancer (e.g., pancreatic cancer) and other diseases.

Abstract: The present invention provides an enhanced DC-NC (eDC-NC) system and method that enables ultra-reliable networking, provides near-instant latency, reduces power consumption while recovering from simultaneous multiple link/node failures and improves the throughput for a wide variety of network architectures.

Abstract: Compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. Pharmaceutical compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. A method for treating cancer is provided.

Abstract: There is provided a method of decoding/encoding an image. The method of the present invention includes: receiving a transform picture reference skip flag; determining whether the transform picture reference skip flag is on or off; and performing inter prediction on a current block on the basis of the transform picture reference skip flag.

Abstract: The subject invention provides methods, assays and products for detecting small-molecules in a sample, in particular, in both clinical and field settings. The method for detecting a small-molecule target in a sample comprises providing a sample, contacting the sample with an aptamer-based sensor selective for the small-molecule target, and sensitively and rapidly detecting the small-molecule target in the sample. Specifically, the method utilizes EATR-amplified small-molecule sensors based on cooperative binding split aptamers (CBSAs).

Abstract: A general methodology for the development of sensitive and selective sensors that can achieve a low cost detection of glucose without using enzymes is disclosed. The method uses carbon nanofiber (CNF) array electrodes for the electrochemical detection of glucose. CNFs grown by plasma enhanced chemical vapor deposition (PECVD) with diameters ranging from 13-160 nm and a height of approximately one micrometer are preferred. The CNFs have a sensitivity of 2.7 ?A/mM cm2 and detection limit of 2 mM. Also provided are methods of preparing the CNF sensors and kit components. Methods of using such CNF sensors for detecting target agents, particularly glucose, are also provided.

Abstract: The present invention relates to a light-emitting device for light amplification using graphene quantum dots and a method of manufacturing the same, which includes a first conductive semiconductor base layer; a plurality of nanowires disposed on the first conductive semiconductor base layer and including a first conductive semiconductor core, an active layer, and a second conductive semiconductor layer sequentially formed from inside to outside; and a graphene quantum dot coating layer disposed on one or both of a surface and an interior of the nanowire, thereby providing a light-emitting device which maximizes light extraction and light amplification.

Abstract: The present invention relates to a method of transporting a stem cell population, the method comprising transporting the stem cell population contacted with a liquid carrier. In addition, the present invention concerns a method of treating a subject having a disease, the method comprising topically administering a defined mesenchymal stem cell population to the subject, wherein the mesenchymal stem cell population is administered within about 96 hours from the time point the mesenchymal stem cell population has been harvested. Also concerned is a unit dosage comprising about 20 million cells, of about 15 million cells, of about 10 million cells, of about 5 million cells, of about 4 million cells, of about 3 million cells, of about 2 million cells, of about 1 million cells, of about 0.5 million cells, of about 0.25 million cells or of less than 0.25 million cells of a defined mesenchymal stem cell population.

Abstract: A prosthetic device is provided including (a) an ankle component, (b) a foot component coupled to the ankle component, wherein the foot component has a longitudinal length extending at least partially along a sagittal plane of a user when the prosthetic device is in use, wherein the foot component has a thickness extending at least partially along a transverse plane of a user when the prosthetic device is in use, and (c) a coupling mechanism positioned between the foot component and the ankle component, wherein the coupling mechanism couples a rotation of the foot component with respect to the sagittal plane to a rotation of the foot component with respect to the transverse plane.

Abstract: The invention relates to compositions for inhibiting or agonizing quorum sensing (QS) pathways to repress biofilm formation, biofilm streamer formation, virulence factor production, and/or infections (including bacterial infections and bacterial infections with resistance to antibiotics) by: (a) a monotherapy using novel compounds, such as small molecule inhibitors or agonists, to inhibit or activate QS activation pathways and/or (b) a combination therapy including novel compounds to inhibit or activate QS and/or to sensitize bacteria to phage along with phage therapy. These compositions can be used to treat patients having infections. Additionally, these compositions can be used to treat surfaces/areas known to contain human pathogens notorious for causing hospital-acquired infections (such as intravenous catheters, implants, medical devices) as well as fatal infections that occur outside of health care settings.

Abstract: Devices and methods for Terahertz (THz) sensing/detection, imaging, spectroscopy, and communication are provided. A graphene-based field effect transistor (FET) can have a quality factor of greater than 400 and a responsivity of at least 400 Volts per Watt. A FET sensor can include a substrate, a gate disposed on the substrate, an insulation layer disposed on the gate and the substrate, a source terminal and a drain terminal disposed on the substrate, and a graphene layer disposed on the insulation layer.

Abstract: An acoustoelectric image-guided therapy system and method for applying acoustoelectric image-guided therapy are disclosed. Embodiments are directed to therapy systems and methods that utilize and are based on acoustoelectric imaging. The acoustoelectric imaging may be combined with focused therapies such as ultrasound, ablation, or hyperthermia for treatment of, for example, acute or chronic conduction abnormalities (e.g., neuropathy, arrhythmia, epilepsy, etc.). Current-density maps are obtained near the region of interest using acoustoelectric imaging techniques. Targeting of the region of interest is then identified for therapy based on the current-density maps. Treatment of the targeted region of interest is then employed while optionally monitoring bioelectric properties using real-time feedback from the acoustoelectric imaging. Imaging and therapy may be automatically co-registered. Standard electrophysiology (e.g., ENG, ECG, EEG, etc.

Abstract: The present invention discloses a system and method designed to secure computerized security processes via an MPC based biometric comparison. Such security processes can be operated between a computerized device operated by a user and a third-party server, or a third-party application executed by a computerized device. The MPC based biometric comparison process utilized to secure the security process can be operated by at least one server and in some cases, a computerized device operated by the user. Said servers may operate a Distributed Security Module, (DSM Server), designed to participate in multi-party computation (MPC) processes. The DSM server may be configured to use the MPC based biometric comparison process to compare a biometric data sample provided by the computerized device with a biometric data reference stored in the DSM server.

Abstract: Disclosed herein is a non-flammable sodium-ion battery having a cathode and an anode and which uses an electrolyte that includes NaBF4 and a glyme solvent, where the battery has an average voltage of from 1.5 V to 6.0 V and has a coulombic efficiency after 5 charge/discharge cycles of at least 90%.

Abstract: Methods are disclosed herein for identifying a compound of use in treating a condition treatable by metformin. The methods include determining if the test compound binds a subunit of the mitochondrial electron transport complex IV, and/or alters the function of the mitochondrial electron transport complex IV. Methods for treating a subject with a condition treatable by metformin, are also disclosed. In some embodiments, the condition is type II diabetes.

Abstract: The present invention relates to a novel ?-1,6-endoglucanase producing gentiobiose or glucose from ?-glucan, and more specifically, the present invention provides an effect of producing gentiobiose or glucose at high yield through ?-1,6-endoglucanase showing ?-1,6-endoglucanase activity on ?-glucan.

Abstract: Treatment of testosterone deficiency in men by a precision medicine approach using a biomarker of activity of UGT2B17 that is involved in testosterone urinary elimination. By inhibiting UGT2B17, alone or in combination with administration of testosterone, testosterone deficiency in men can be treatable. Further, a method of dose selection for precise dosing of UGT2B17 substrate drugs is provided. Additionally, methods for safe dosing of pharmaceutical agents that undergo UGT2B17-mediated acyl glucuronidation are provided.